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Abstract
Xanthomatous skin lesions and arthritis in children are not a common association. We present the
case of a 3 year old girl who presented with xanthomatous lesions in the periungual region of both
hands, around the nares and on her forehead, associated with significant arthritis that was clinically
compatible with multicentric reticulohistiocytosis. However, pathology of the xanthomatous
lesions was more suggestive of papular xanthoma, a disease that is not associated with arthritis.
Based on her presentation and the negative lipid workup, she was treated for presumed
multicentric reticulohistiocytosis. Multiple treatment strategies were utilized, with improvement
on a combination of infliximab, methotrexate, and prednisone. We review the different diagnoses
that should be considered in children with xanthomas and arthritis as well as the different
pharmacologic therapies used in children with multicentric reticulohistiocytosis.
Background
Xanthomatous disorders are uncommon in childhood.
The most common xanthomatous disorders seen in child-
hood including xanthoma disseminatum, papular xan-
thoma, and benign cephalic histiocytosis are not
associated with arthritis. Arthritis in childhood is also rel-
atively rare, with juvenile idiopathic arthritis accounting
for the majority of cases. When xanthomatous lesions and
arthritis are seen together in childhood, the differential
diagnosis is limited to a relatively short list of exceedingly
rare disorders which can be subdivided into two sub-
groups based on whether or not there are associated lipid
abnormalities. When a child presents with xanthomas,
arthritis, and elevated lipid levels, familial hyperlipidemia
type II and sitosterolemia must be considered; when the
lipid levels are normal, the differential includes Von
Gierke glycogen storage disease, Farber disease, multicen-
tric reticulohistiocytosis (MRH), and familial and histio-
cytic dermatoarthritis. We present a case report of a 3 year
old female with a clinical picture most consistent with
MRH but with pathology more suggestive of papular xan-
thoma.
Case Presentation
A previously healthy 3 year old girl presented to our Pedi-
atric Dermatology Clinic in April of 2007 with a 6 month
history of a papular skin eruption on the finger nail mar-
gins of her hands bilaterally, her scalp, and around the
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nares (fig 1). These symptoms were associated with signif-
icant arthralgia affecting her wrists and knees. There were
no other associated symptoms. Her family history was
negative for lipid disorders, dermatologic conditions, and
chronic inflammatory conditions.
The physical examination revealed multiple flesh colored
to slightly pink, flat-topped, smooth papules lined up in a
row in the periungual skin on every finger of both hands,
as well as the margin of the nares, forehead, and scalp. The
musculoskeletal examination demonstrated unequivocal
polyarthritis. There was swelling, loss of range of motion,
and pain with movement in both elbows. There was syn-
ovial thickening and pain with flexion in both wrists.
There were flexion contractures of the second and third
proximal interphalangeal joints of both hands. Effusions
and synovial thickening were present in both knees.
Laboratory results showed a normal complete blood
count, hepatic profile, renal profile, and lipid profile
(cholesterol 128 mg/dL, low density lipoprotein 83 mg/
dL, high density lipoprotein 30 mg/dL, triglycerides 75
mg/dL). Lactate, uric acid, serum sterol, and urine organic
acid levels (desmosterol, lathosterol, campesterol and
sitosterol) were all within normal limits. ESR and CRP
were within normal limits. Serum protein electrophoresis
revealed no significant abnormalities. Lyme serology,
anti-nuclear antibodies, and rheumatoid factor were neg-
ative. PPD was negative.
Bilateral hand X-rays demonstrated mild diffuse osteope-
nia without periosteal reaction, soft tissue swelling in the
digits, most striking at the base of the fingernails and a
radiolucency at the base of the left third proximal pha-
lanx. A CT scan of the chest, abdomen and pelvis was
unremarkable. CT scan of the neck showed multiple, less
than 2 cm lymph nodes. A glenohumeral joint effusion
was noted as well.
Skin biopsies were obtained from the nail fold and scalp.
The histology sections showed a dome-shape lesion with
dermal infiltrate composed of foamy histiocytes and a few
admixed lymphocytes (fig 2). Multinucleated giant cells
and Touton type giant cells were not observed. There was
upward migration of cells with clear, foamy, and vacu-
olated cytoplasm within the overlying epidermis. PAS
stains were negative for glycogen deposition and fungal
organisms. AFB stains were negative. Immunostaining
with CD68 was positive, and CD1a stained only a few
intraepidermal and rare dermal cells. Factor XIIIa stained
a few scattered cells. These biopsies where read by multi-
ple pathologists as consistent with papular xanthoma.
Additional biopsies of synovium and additional skin nod-
ule both showed foamy histiocytes with scattered lym-
phocytes arranged in sheets. Cytoplasm ranged from clear
to bubbly to finely granular. CD68 and lysozyme stained
strongly positive in histiocytes. Formal evaluation of the
patient by an ophthalmologist, oncologist, and metabolic
specialist revealed no additional findings.
The child was diagnosed with MRH based on her clinical
presentation, even though histopathology was not classic
for this disorder, and followed in pediatric rheumatology
clinic. She was started on naproxen without major
improvement in the joint complaints; methotrexate was
then added at a dose of 5 mg (0.4 mg/kg) by mouth once
a week and later increased to 7.5 mg (0.6 mg/kg) subcuta-
neously once a week without major improvement.
Hydroxychloroquine 75 mg (6.25 mg/kg) by mouth per
day was added. Subcutaneous nodules of about 2 × 1 × 2
cm were noted on the upper portion her arms bilaterally
in the region of the axilla and diagnosed as synovial cysts
by ultrasound. X ray of the shoulders revealed subtendi-
nous erosion of bone in the humerus and distal clavicle
remodeling (fig 3). Oral prednisone 1.7 mg/kg/day was
started, and there was almost complete resolution of the
xanthomatous lesions and moderate improvement in her
arthritis. Prednisone was tapered to 1 mg/kg.
However, she continued to have multiple joint effusions
and decreased range of motion in her PIP joints. There-
fore, etanercept was added at a dose of 20 mg (1.25 mg/
kg) subcutaneously every week. Methotrexate was
increased to 12.5 mg (0.8 mg/kg). She had a partial initial
response to etanercept with some improvement in the
range of motion of her MCP's and wrists. However, after 3
months on etanercept, the patient had significant ongoing
polyarthritis, so the etanercept dose was increased to 25
mg (1.5 mg/kg), and methotrexate was increased to 15 mg
(0.9 mg/kg). As her prednisone was tapered very slowly, a
few tiny xanthomatous lesions reappeared. Due to wors-
ening polyarthritis, etanercept was discontinued, and inf-
liximab was started at a dose of 10 mg/kg intravenously.
After 2 infusions given 2 weeks apart, the patient was
noted to have improvement with resolution of multiple
joint effusions and improved range of motion. In addi-
tion, all xanthomas disappeared. The infliximab infusions
Figures 1a and 1b. Figure 1
Figures 1a and 1b. Pink, flat topped, smooth papules over-
lying the proximal nail folds of the hands bilaterally (1a), and 
on the forehead (1b).     Pediatric Rheumatology 2009, 7:15 http://www.ped-rheum.com/content/7/1/15
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were continued every 4 weeks. Methotrexate was contin-
ued at 0.9 mg/kg subcutaneously per week. Prednisone
was tapered further, but patient developed recurrent pol-
yarthritis and new xanthomas over her fingers. Unfortu-
nately, her synovitis did not improve further when
infliximab was increased to 20 mg/kg.
Discussion
MRH is a systemic non-Langerhans cell histiocytosis first
described in 1937 by Weber and Freudenthal [1]. Later,
Goltz and Laymon coined the term multicentric reticulo-
histiocytosis [1]. About 200 cases have been reported
since first described, but only about 10 of these cases had
onset in childhood. Of these, the youngest case described
is that of a 6 year old child [2].
MRH is predominantly a condition of the adult popula-
tion, and it is more common in females with a ratio of
about 1.85 females per 1 male [1]. MRH is characterized
by severe destructive bilateral and symmetric arthritis,
mainly affecting the interphalangeal joints, shoulders,
wrists, and hips. Characteristic skin findings are described
as cutaneous nodules or papules that are usually localized
in the periungual region, pinnae of the ears, nasal folds,
and scalp. The pathognomonic "coral bead sign", which
our patient demonstrated, is present in about 26% of the
cases [1]. Systemic findings such us fever and anemia are
absent in most. An association with malignancy has been
reported, but no single neoplastic disorder is directly asso-
ciated with MRH. The co-occurrence of malignancy is
about 15 to 25%. The reported malignancies associated
with this condition include melanoma, lymphoma, breast
cancer, and ovarian cancer [3,4]. MRH has also been asso-
ciated with autoimmune diseases [3].
Histologic evaluation usually demonstrates multinucle-
ated giant cells with a fine, ground-glass appearance, and
in some cases, foamy or vacuolated histiocytes, as in our
patient's case and that of a 14 year old girl [5,6]. Some
authors report that early in the disease there are more eosi-
nophils, lymphocytes and histiocytes with fewer number
of multinucleated giant cells which increase as the disease
progresses, which could explain why there were no giant
cells present on our patient's biopsy [7]. There is an asso-
ciated lymphocytic infiltrate. Immunohistochemistry is
variable, but in most cases, staining is positive for CD68,
CD4, CD45, HLA-DR, and lysozyme, but negative for
S100, CD20, and factor XIIIa [7]. While the clinical pres-
entation and course of our patient is consistent with
MRH, the histopathology and age of our patient are atyp-
ical for this disorder. The biopsy was positive for CD68
and lysozyme but did not demonstrate typical MRH cells.
Radiologic findings of MRH may be similar to rheuma-
toid arthritis, psoriatic arthritis, and osteoarthritis, but
subtle differences may help to differentiate them. Radio-
graphically, MRH presents as periarticular soft tissue
swelling and juxta-articular erosions of the joints of the
hands symmetrically. The erosions spread centrally and
cause separation of the bony areas [8]. Osteoporosis has
not been described, but osteopenia was found in our
patient and was reported in a 14 year old African Ameri-
can girl [9]. There can be compromise of the atlantoaxial
joint causing subluxation and instability. The disease can
progress to arthritis mutilans [8].
The differential diagnosis of xanthomas and arthritis is
short but includes familial hypercholesterolemia type II
and sitosterolemia. Familial Hypercholesterolemia type II
is a common, autosomal dominant genetic disorder
caused by a mutation in the LDL receptor gene that may
present with xanthomatous lesions and oligoarthritis.
Figures 2a and 2b. Figure 2
Figures 2a and 2b. Sections showed a dome-shape lesion 
with dermal infiltrate composed of foamy histiocytes.  Few 
admixed lymphocytes were noted.  Multinucleated giant cells 
and Touton type giant cells were not observed.  There was 
upward migration of cells with clear, foamy, and vacuolated 
cytoplasm with in the overlying epidermis. a) 25x, H&E stain-
ing; b) 400x, H&E staining.
Figures  3a and 3b. Figure 3
Figures  3a and 3b. X-ray images of the right shoulder 
show subtendinous resorption of bone of proximal humerus 
(figure 3A) followed by healing of this lesion (figure 3B) after 
one year of immunosuppressive medications.Pediatric Rheumatology 2009, 7:15 http://www.ped-rheum.com/content/7/1/15
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Sitosterolemia is a rare, autosomal recessive lipid disorder
characterized by extremely elevated plasma plant sterol
levels. It is clinically characterized by tuberous skin and
tendon xanthomatous lesions, arthritis, and premature
vascular disease. Our patient had normal lipid levels and
sterol screening which ruled out these diagnoses.
Other disorders like Von Gierke glycogen storage disease
and Farber's disease can present with xanthomas and joint
complaints. The lack of systemic involvement and pro-
gressive course did not support these diagnoses in our
patient. The lack of osteocondrodystrophy, ocular find-
ings, and family history in our patient excluded familial
histiocytic dermatoarthritis and dermochondrocorneal
dystrophy as possible diagnoses. Xanthoma dissemina-
tum, also part of the non-Langerhans histiocytic disorder
spectrum, typically occurs in teenagers and young adults.
The skin lesions are described as yellow to brown growths
forming plaques and nodules that can present anywhere
on the skin but most commonly in flexural areas of the
extremities, the eyelids, and mucosae; visceral involve-
ment has been described. Case reports of skeletal involve-
ment presenting with limb pain caused by bone
infiltration of xanthomas exist, but no cases of joint infil-
tration or associated arthritis have been published. Other
non- LCH disorders such as juvenile xanthogranuloma
(JXG) and generalized eruptive histiocytomas (GEH) can
present with xanthomatous lesions. Skin biopsy of these
lesions shows a characteristic vacuolated histiocytic infil-
trate which contains Touton giant cells in 85% of the cases
and a characteristic positivity of the lesions to factor XIIIa,
CD68, CD163, fascin, and CD14 but negative S100 and
CD1 on immunohistochemistry [10]. The histologic find-
ings of JXG and GEH are different from those of our
patient. Moreover, these entities are not known to be asso-
ciated with arthritis.
Despite the clinical picture being consistent with MRH,
the histologic examination of the skin lesions and the syn-
ovium were consistent with a diagnosis of papular xan-
thoma (PX). This entity, a normo-lipemic, non-
Langerhans cell histiocytosis, is also a very rare disease in
childhood. The cases reported in children have been char-
acterized clinically by the presence of generalized yellow
to brown papules and papulonodules on the face, trunk
and limbs and a distinctive resolution in 1 to 5 years leav-
ing anatoderma like scars in 60% of the case [11]. Histo-
logic examination of the lesions shows similar
characteristics as the ones seen in our patient: a dermal
infiltrate of foamy histiocytes; however, our patient did
not have Touton giant cells that are commonly be seen in
PX. In popular xanthoma, histiocytes are CD68, KiM1p,
and HAM 56 positive but negative for XVIIIa, S-100, lys-
ozyme and CD56 [11]. Usually, these patients have no
systemic involvement, and there is no report in the litera-
ture of an association with arthritis.
Multiple treatment options have been utilized in patients
with MRH including NSAIDs, cyclophosphamide, azathi-
oprine, methotrexate, hydroxychloroquine, corticoster-
oids and, recently, biologics with no definitive treatment
regimen that can control the disease in all cases [12-14].
Several case reports in children have described acceptable
results with NSAIDs or methotrexate alone [2,6]. For
severe cases, more aggressive therapy is warranted. Sys-
temic steroids can be effective for the arthritis, serositis,
and xanthomatous skin lesions as was seen in our patient,
but this is not a good long term treatment option given
the toxicity.
The tumor necrosis factor (TNF) antagonists are a logical
consideration given the evidence of increased TNF-α in
patients with MRH [15]. Etanercept, an α-TNF receptor
fusion protein, has been reported efficacious in some
adult patients with difficult to treat MRH, but has not
been successful in other reports [16]; the use of etanercept
has not been reported in children with MRH. Etanercept
did not completely control the synovitis in our patient.
Infliximab, a monoclonal antibody against human-TNF-
α, has been used in combination with methotrexate and
prednisolone, with success in two case reports [12,17];
however, no benefit was achieved with infliximab in com-
bination with methotrexate in another patient [13]. Adal-
imumab, a recombinant human IgG1 monoclonal
antibody against TNF-α, has also been reported to be use-
ful in the treatment of MRH [14].
There have also been reports of improved disease control
when bisphosphonates are either added to or used as
monotherapy to the treatment regimen in MRH [18].
Multinucleated cells from cutaneous nodules in MRH
have been found to stain strongly with osteoclast markers,
suggesting osteoclast differentiation [18]. In MRH,
RANKL and macrophage colony stimulating factor stimu-
late synovial fluid macrophages to differentiate into oste-
oclasts [18]. Bisphosphonate therapy can decrease RANKL
levels and promote osteoclast apoptosis. Therefore,
bisphosphonates could be a promising treatment option
for children with MRH, but more studies need to be con-
ducted.
Preventing erosive joint destruction, particularly blocking
the progression of MRH to arthritis mutilans, is the ulti-
mate goal in treatment, and the search for an ideal treat-
ment regimen continues. Corticosteroids seem to be very
effective, but side effects limit its long term use especially
in growing children. TNF inhibitors may be of benefit to
some, although they were not very effective in our patient
in that the effects were not sustained, and the use of TNF
inhibitors did not have a steroid sparing effect. Combina-
tion regimens of several different immunosuppressive
drugs seem to be the most effective way to control the dis-Publish with BioMed Central    and   every 
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ease. Bisphosphonates are another unexplored treatment
option to consider in children with MRH.
Abbreviations
MRH: Multicentric Reticulohistiocytosis; CT: computed
tomography; NSAID: non: steroidal anti: inflammatory
drug; MCP's: metacarpophalangeal joints; PIP: proximal
interphalangeal.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CAB, PJF and AZ are the treating and consulting physi-
cians. CM prepared the manuscript. CAB, PJF, AZ, BG
reviewed and edited the manuscript.
References
1. Luz FB, Gaspar NK, Gaspar AP, Carneiro S, Ramos-e-Silva M: Multi-
centric reticulohistiocytosis: a proliferation of macrophages
with tropism for skin and joints, part I.  Skinmed 2007,
6(4):172-8.
2. Candell C: A case of multicentric reticulohistiocytosis in a 6-
year-old child.  J Rheumatol 1998, 25(4):794-7.
3. Luz FB, Gaspar NK, Gaspar AP, Carneiro S, Ramos-E-Silva M: Multi-
centric reticulohistiocytosis: a proliferation of macrophages
with tropism for skin and joints, part II.  Skinmed 2007,
6(5):227-33.
4. Kuramoto Y, Iizawa O, Matsunaga J, Nakamura N, Tagami H: Devel-
opment of Ki-1 lymphoma in a child suffering from multicen-
tric reticulohistiocytosis.  Acta Derm Venereol 1991, 71(5):448-9.
5. Luz FB, Gaspar TAP, Kalil-Gaspar N, Ramos-e-Silva M: Multicentric
reticulohistiocytosis.  J Eur Acad Dermatol Venereol 2001,
15(6):524-31.
6. Outland JD, Keiran SJ, Schikler K, Callen JP: Multicentric reticulo-
histiocytosis in a 14-year-old girl.  Pediatr Dermatol 2002,
19(6):527-531.
7. Gorman JD, Danning C, Schumacher HR, et al.: Multicentric retic-
ulohistiocytosis: case report with immunohistochemical
analysis and literature review.  Arthritis Rheum 2000, 43:930.
8. Friedman P, Kalisher L: Multicentric reticulohistiocytosis in a
child: radiologic findings and clinical correlation.  Can Assoc
Radiol J 1998, 49(6):378-80.
9. Raphael SA, Cowdery SL, Faerber EN, Lischner HW, Schumacher HR,
Tourtellotte CD: Multicentric reticulohistiocytosis in a child.  J
pediatr 1989, 114(2):266-9.
10. Weitzman  S, Jaffe  R: Uncommon histiocytic disorders: the
non-Langerhans cell histiocytoses.  Pediatr Blood Cancer 2005,
45(3):256-64.
11. Breier F, Zelger B, Reiter H, Gschnait F, Zelger BW: Papular xan-
thoma: a clinicopathological study of 10 cases.  J Cutan Pathol
2002, 29(4):200-206.
12. Lee MW, Lee EY, Jeong YI, Choi JH, Moon KC, Koh JK: Successful
treatment of multicentric reticulohistiocytosis with a combi-
nation of infliximab, prednisolone and methotrexate.  Acta
Derm Venereol 2004, 84(6):478-9.
13. Sellam J, Deslandre CJ, Dubreuil F, Arfi S, Kahan A: Refractory mul-
ticentric reticulohistiocytosis treated by infliximab: two
cases.  Clin Exp Rheumatol 2005, 23(1):97-9.
14. Liang GC, Granston AS: Complete remission of multicentric
reticulohistiocytosis with combination therapy of steroid,
cyclophosphamide, and low-dose pulse methotrexate. Case
report, review of the literature, and proposal for treatment.
Arthritis Rheum 1996, 39(1):171-4.
15. Nakamura H, Yoshino S, Shiga H, Tanaka H, Katsumata S: A case of
spontaneous femoral neck fracture associated with multi-
centric reticulohistiocytosis: oversecretion of interleukin-
1beta, interleukin-6, and tumor necrosis factor alpha by
affected synovial cells.  Arthritis Rheum 1997, 40:2266-70.
16. Kovach BT, Calamia KT, Walsh JS, Ginsburg WW: Treatment of
multicentric reticulohistiocytosis with etanercept.  Arch Der-
matol 2004, 140:919-921.
17. Kalajian AH, Callen JP: Multicentric reticulohistiocytosis suc-
cessfully treated with infliximab: an illustrative case and eval-
uation of cytokine expression supporting anti-tumor
necrosis factor therapy.  Arch Dermatol 2008, 144(10):1360-6.
18. Codriansky KA, Rünger TM, Bhawan J, Kantarci A, Kissin EY: Multi-
centric reticulohistiocytosis: a systemic osteoclastic disease?
Arthritis Rheum 2008, 59(3):444-8.